TME Therapeutics (Biotechnology) Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

TME Therapeutics (Biotechnology) General Information

Description

Operator of a stem cell research and development company intended to development of stem-cell-based cultured cell therapy. The company provides coated surfaces that support the attachment and expansion of various stem cells including mesenchymal stem cells, satellite stem cells and neural stem cells, enabling users to get products related to stem cell expansion under fully defined conditions.

Contact Information

Website
www.tmet.co.kr
Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Corporate Office
  • 204, Convensia-daero
  • Number 208, Insta 2 building, Incheon Startup Park
  • Incheon, Yeonsu-gu
  • South Korea
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Vertical(s)
Corporate Office
  • 204, Convensia-daero
  • Number 208, Insta 2 building, Incheon Startup Park
  • Incheon, Yeonsu-gu
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TME Therapeutics (Biotechnology) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 13-Jul-2023 Completed Out of Business
1. Accelerator/Incubator Completed Generating Revenue
To view TME Therapeutics (Biotechnology)’s complete valuation and funding history, request access »

TME Therapeutics (Biotechnology) Patents

TME Therapeutics (Biotechnology) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023158285-A1 Gf binding ecm mimetic coated microcarrier Inactive 21-Feb-2022
CA-3201919-A1 Protein substrate to bind growth factor Pending 16-Dec-2020
EP-4244241-A1 Protein substrate to bind growth factor Pending 16-Dec-2020
EP-4244241-A4 Protein substrate to bind growth factor Pending 16-Dec-2020
JP-2025061045-A Protein substrate to bind growth factor Active 16-Dec-2020 C07K14/78
To view TME Therapeutics (Biotechnology)’s complete patent history, request access »

TME Therapeutics (Biotechnology) FAQs

  • When was TME Therapeutics (Biotechnology) founded?

    TME Therapeutics (Biotechnology) was founded in 2018.

  • Where is TME Therapeutics (Biotechnology) headquartered?

    TME Therapeutics (Biotechnology) is headquartered in Incheon, South Korea.

  • What industry is TME Therapeutics (Biotechnology) in?

    TME Therapeutics (Biotechnology)’s primary industry is Biotechnology.

  • Is TME Therapeutics (Biotechnology) a private or public company?

    TME Therapeutics (Biotechnology) is a Private company.

  • What is TME Therapeutics (Biotechnology)’s current revenue?

    The current revenue for TME Therapeutics (Biotechnology) is .

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process